Clinical significance of mismatch repair gene expression in sporadic colorectal cancer

Sun,Zhenqiang; Yu,Xianbo; Wang,Haijiang; Zhang,Shuo; Zhao,Zeliang; Xu,Ruiwei

doi:10.3892/etm.2014.1927

Clinical significance of mismatch repair gene expression in sporadic colorectal cancer

Authors:
- Zhenqiang Sun
- Xianbo Yu
- Haijiang Wang
- Shuo Zhang
- Zeliang Zhao
- Ruiwei Xu
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Gastrointestinal Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Pathology, The Second Affiliated Hospital, Urumqi, Xinjiang 830011, P.R. China, Infection & Statistical Office, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China
Published online on: August 22, 2014 https://doi.org/10.3892/etm.2014.1927
Pages: 1416-1422

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mismatch repair (MMR) genes play an important role in the occurrence and development of sporadic colorectal cancer; however, the effect of MMR genes on clinicopathological features and prognosis remains unclear. The aim of the present study was to observe the clinical significance of MMR gene expression in sporadic colorectal cancer. Clinicopathological data and postoperative samples from 404 patients with sporadic colorectal cancer were obtained from the Affiliated Tumor Hospital of Xinjiang Medical University. The immunohistochemistry PV‑9000 two‑step method was performed to measure the protein expression of human mutL homolog 1 (hMLH1), human mutS homolog (hMSH) 2, human postmeiotic segregation increased 2 (hPSM2) and hMSH6. Differences in clinicopathological features, family history and survival time subsequent to surgery between groups with normal and aberrant MMR protein (MMRP) expression were compared. A total of 27.23% of all patients showed aberrant nuclear staining of MMRP. Among the patients with aberrant MMRP expression, a higher proportion of patients showed aberrant expression of more than one type of MMRP than aberrant expression of only one type of MMRP. Aberrant expression of hMLH1/hPSM2 was most commonly observed (29/404). In addition, aberrant MMRP expression in colorectal cancer was indicated predominantly in the right hemicolon. Histological type primarily showed mucinous adenocarcinoma. In addition, with increasing body mass index (BMI), the MMRP deficiency rate was also shown to increase gradually. There was a close association between MMRP expression deficiency and family history of cancer (P<0.05). For TNM stage III patients, the Kaplan‑Meier survival curve showed that the aberrant MMRP expression group had a three‑year disease‑free survival (DFS) rate of 66.67%, which was longer than the DFS rate of the normal group (55.41%), with no statistical difference (P>0.05). In conclusion, the immunohistochemistry PV‑9000 two‑step method can be used to measure MMRP expression in colorectal cancer. Aberrant MMRP expression is closely correlated with tumor location, histological type, BMI and tumor family history in sporadic colorectal cancer. Aberrant MMRP expression may have an effect on the prognosis of stage III patients.

View Figures

View References

1	Adib SM, Tabbal N, Hamadeh R and Ammar W: Geographic epidemiology in a small area: cancer incidence in Baakline, Lebanon, 2000–2008. East Mediterr Health J. 19:320–326. 2013.PubMed/NCBI
2	Van Engeland M, Derks S, Smits KM, et al: Colorectal cancer epigenetics: complex simplicity. J Clin Oncol. 29:1382–1391. 2011.PubMed/NCBI
3	Blokhuis MM, Pietersen GE, Goldberg PA, et al: Lynch syndrome: the influence of environmental factors on extracolonic cancer risk in hMLH1 c. C1528T mutation carriers and their mutation-negative sisters. Fam Cancer. 9:357–363. 2010. View Article : Google Scholar : PubMed/NCBI
4	Fishel R, Lescoe MK, Rao MR, et al: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 75:1027–1038. 1993. View Article : Google Scholar
5	Aaltonen LA, Salovaara R, Kristo P, et al: Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 338:1481–1487. 1998. View Article : Google Scholar : PubMed/NCBI
6	Mureşan F, Simescu R, Domşa I, et al: Immunohistochemical screening of hMLH1 and hMSH2 gene mutations in patients diagnosed with colorectal cancer and microsatellite instability suspicion. Chirurgia (Bucur). 106:775–780. 2011.(In Romanian).
7	Wei W, Liu F, Liu L, et al: Distinct mutations in MLH1 and MSH2 genes in hereditary non-polyposis colorectal cancer (HNPCC) families from China. BMB Rep. 44:317–322. 2011. View Article : Google Scholar : PubMed/NCBI
8	Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst. 89:1758–1762
9	Lynch HT and Smyrk T: Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer. 78:1149–1167. 1996. View Article : Google Scholar : PubMed/NCBI
10	Win Aung Ko, Young Joanne P, et al: Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 30:958–964. 2012.PubMed/NCBI
11	Wada-Hiraike O, Yano T, Nei T, et al: The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha. Br J Cancer. 92:2286–2291. 2005. View Article : Google Scholar : PubMed/NCBI
12	Park IJ, Kim HC, Kim JS, et al: Correlation between hhMLH1/hhMSH2 and p53 protein expression in sporadic colorectal cancer. Hepatogastroenterology. 52:450–454. 2005.PubMed/NCBI
13	Vreeswijk MP and van der Klift HM: Analysis and interpretation of RNA splicing alterations in genes involved in genetic disorders. Methods Mol Biol. 867:49–63. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sun ZQ, Yu XB, Wang HJ, et al: Relationship between Aberrant Expression of hMSH2 and prognosis in patients with sporadic colorectal cancer. Canc Cell Rec. 2:e47–e54. 2014.
15	Belcheva A, Irrazabal T, Robertson SJ, et al: Gut microbial metabolism drives transformation of msh2-deficient colon epithelial cells. Cell. 158:288–299. 2014. View Article : Google Scholar : PubMed/NCBI
16	Cunningham JM, Kim CY, Chirstensen ER, et al: The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet. 69:780–790. 2001. View Article : Google Scholar : PubMed/NCBI
17	Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 363:558–561. 1993. View Article : Google Scholar : PubMed/NCBI
18	Popat S, Hubner R and Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar : PubMed/NCBI
19	Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
20	Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 28:3219–3226. 2010. View Article : Google Scholar : PubMed/NCBI
21	Holzhüter J, Rösch T, Block A, et al: A 44-year-old woman with hereditary nonpolyposis colon carcinoma: screening examinations for non-colonic tumors. Internist (Berl). 54:353–358. 2013.(In German).
22	Plevová P, Krepelová A, Papezová M, et al: Immunohistochemical detection of the hMLH1 and hMSH2 proteins in hereditary non-polyposis colon cancer and sporadic colon cancer. Neoplasma. 51:275–284. 2004.PubMed/NCBI
23	Lindor NM, Burgart LJ, Leontovich O, et al: Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 20:1043–1048. 2002. View Article : Google Scholar : PubMed/NCBI
24	Ruszkiewicz A, Bennett G, Moore J, et al: Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathology. 34:541–547. 2002. View Article : Google Scholar : PubMed/NCBI
25	Shia J, Klimstra DS, Nafa K, et al: Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol. 29:96–104. 2005. View Article : Google Scholar : PubMed/NCBI
26	Marcus VA, Madlensky L, Gryfe R, et al: Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol. 23:1248–1255. 1999. View Article : Google Scholar : PubMed/NCBI
27	Joost P, Veurink N, Holck S, et al: Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol. 9:1262014. View Article : Google Scholar : PubMed/NCBI
28	Haghighi MM, Aghagolzadeh P, Zadeh SM, et al: Telomere shortening: a biological marker of sporadic colorectal cancer with normal expression of p53 and mismatch repair proteins. Genet Test Mol Biomarkers. 18:236–244. 2014. View Article : Google Scholar : PubMed/NCBI
29	Hawkins NJ and Ward RL: Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J Natl Cancer Inst. 93:1307–1313. 2001. View Article : Google Scholar : PubMed/NCBI
30	Kupčinskaitė-Noreikienė R, Skiecevičienė J, Jonaitis L, et al: CpG island methylation of the MLH1, MGMT, DAPK, and CASP8 genes in cancerous and adjacent noncancerous stomach tissues. Medicina (Kaunas). 49:361–366. 2013.PubMed/NCBI
31	Gomes A, Reis-Silva M, Alarcão A, et al: Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung. Rev Port Pneumol. 20:20–30. 2014. View Article : Google Scholar : PubMed/NCBI
32	Molaei M, Mansoori BK, Ghiasi S, et al: Colorectal cancer in Iran: immunohistochemical profiles of four mismatch repair proteins. Int J Colorectal Dis. 25:63–69. 2010. View Article : Google Scholar : PubMed/NCBI
33	Bellizzi AM and Frankel WL: Colorectal cancer due to deficiency in DNA mismatch repair function: a review. Adv Anat Pathol. 16:405–417. 2009. View Article : Google Scholar : PubMed/NCBI
34	Valle L, Perea J, Carbonell P, et al: Clinicopathologic and pedigree differences in amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. J Clin Oncol. 25:781–786. 2007. View Article : Google Scholar
35	Jass JR: HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer. 3:93–100. 2004. View Article : Google Scholar : PubMed/NCBI
36	Raskin GA, Ianus GA, Kornilov AV, et al: Immunohistochemical examination of MSH2, PMS2, MLH1, MSH6 compared with the analysis of microsatellite instability in colon adenocarcinoma. Vopr Onkol. 60:47–50. 2014.(In Russian).
37	Kim JH and Kang GH: Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol. 20:4230–4243. 2014. View Article : Google Scholar : PubMed/NCBI
38	Goldstein J, Tran B, Ensor J, et al: Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 25:1032–1038. 2014. View Article : Google Scholar : PubMed/NCBI
39	Slattery ML, Levin TR, Ma K, et al: Family history and colorectal cancer: predictors of risk. Cancer Causes Control. 14:879–887. 2003. View Article : Google Scholar : PubMed/NCBI
40	Campbell PT, Cotterchio M, Dicks E, et al: Excess body weight and colorectal cancer risk in Canada: associations in subgroups of clinically defined familial risk of cancer. Cancer Epidemiol Biomarkers Prev. 16:1735–1744. 2007. View Article : Google Scholar : PubMed/NCBI
41	van Duijnhoven FJ, Botma A, Winkels R, et al: Do lifestyle factors influence colorectal cancer risk in Lynch syndrome? Fam Cancer. 12:285–293. 2013.PubMed/NCBI
42	Botma A, Nagengast FM, Braem MG, et al: Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. J Clin Oncol. 28:4346–4353. 2010. View Article : Google Scholar : PubMed/NCBI
43	Win AK, Dowty JG, English DR, et al: Body mass index in early adulthood and colorectal cancer risk for carriers and non-carriers of germline mutations in DNA mismatch repair genes. Br J Cancer. 105:162–169. 2011. View Article : Google Scholar : PubMed/NCBI
44	Sánchez-de-Abajo A, de la Hoya M, van Puijenbroek M, et al: Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. Clin Cancer Res. 13:5729–5735. 2007.
45	Karoui M, Tresallet C, Brouquet A, et al: Colorectal carcinogenesis. 1. Hereditary predisposition and colorectal cancer. J Chir (Paris). 144:13–18. 2007.(In French).
46	Bubb VJ, Curtis LJ, Cunningham C, et al: Microsatellite instability and the role of hhMSH2 in sporadic colorectal cancer. Oncogene. 12:2641–2649. 1996.PubMed/NCBI
47	Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 342:69–77. 2000. View Article : Google Scholar : PubMed/NCBI
48	Sankila R, Aaltonen LA, Järvinen HJ and Mecklin JP: Better survival rates in patients with hMLH1-associated hereditary colorectal cancer. Gastroenterology. 110:682–687. 1996. View Article : Google Scholar : PubMed/NCBI
49	Heinimann K, Scott RJ, Buerstedde JM, et al: Influence of selection criteria on mutation detection in patients with hereditary nonpolyposis colorectal cancer. Cancer. 85:2512–2518. 1999. View Article : Google Scholar : PubMed/NCBI